Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Jonathan D. Schoenfeld(Brigham and Women's Hospital), Robert I. Haddad(Dana-Farber Cancer Institute)
Cited by 340
Related Papers
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|495
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
|JCI Insight|2018|276
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
|British Journal of Cancer|2016|84
A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck
|Clinical Cancer Research|2004|67
Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent Literature
|Advances in Radiation Oncology|2023|16